MLYS reports a deeper Q2 GAAP loss of $2.85 per share, missing estimates as net income rises year-over-year.
Mineralys Therapeutics posted a Q2 GAAP loss of $2.85 per share, missing expectations by $2.30. The wider loss comes despite a rise in total other income, net, to $5.0 million for the quarter ended June 30, 2026.
The company reported $3.5 million in other income for the same period last year. The $1.5 million increase was driven primarily by a $2.3 million gain, though details on the specific contributors were not disclosed.
Shares may face pressure as investors assess the earnings miss against the backdrop of rising income.